The NADINA clinical trial is testing the hypothesis that neoadjuvant (pre-surgery) treatment is more effective than adjuvant (post-surgery) treatment in preventing recurrence after Stage III melanoma diagnosis. It is the world’s first trial to compare neoadjuvant treatment with combination immunotherapy to the current standard adjuvant approach with single agent immunotherapy.
MIA Co-Medical Director Professor Georgina Long AO is the lead national Chief Investigator for NADINA.
The NADINA trial is led by MIA across eight Australian centres – MIA, Peter MacCallum Cancer Centre, #WestmeadHospital, The Alfred, Tasman Health Care, #LakeMacquarieHospital, #FionaStanleyHospital and #PrincessAlexandraHospital.
Nature Medicine’s annual feature named NADINA as one of 11 clinical trials that will shape medicine in 2024.
“These are potentially exciting treatments, but only through these trials can researchers know whether they will benefit patients,” said Ben Johnson, Senior Magazine Editor at Nature Medicine. “The trials highlighted demonstrate the breadth of research taking place and the myriad ways researchers are attempting to tackle issues of global importance.”